PD-L1 expression and deficient mismatch repair in ductal adenocarcinoma of the prostate.


Journal

APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
ISSN: 1600-0463
Titre abrégé: APMIS
Pays: Denmark
ID NLM: 8803400

Informations de publication

Date de publication:
Aug 2019
Historique:
received: 15 03 2019
accepted: 17 05 2019
pubmed: 28 5 2019
medline: 26 7 2019
entrez: 26 5 2019
Statut: ppublish

Résumé

This study aimed to investigate the expression of programmed death receptor ligand 1 (PD-L1) and deficient mismatch repair (dMMR) in ductal adenocarcinoma of the prostate. A tissue microarray of 32 ductal and 42 grade-matched acinar adenocarcinomas was used. Slides were stained for PD-L1, PD-L2, MMR proteins, CD4 and CD8. PD-L1 expression in tumor cells was only seen in 3% (1/34) of ductal and 5% (2/42) of acinar adenocarcinomas (p = 1.0), while PD-L1 expression in tumor-infiltrating immune cells was seen in 29% (10/34) of ductal and 14% (6/42) of acinar adenocarcinomas (p = 0.16). dMMR, as defined by loss of one or more of the MMR proteins, was identified in 5% (4/73) of cases, including 1 ductal and 3 acinar adenocarcinomas. There was a suggested association between infiltration of CD8+ lymphocytes and ductal subtype (p = 0.04) but not between CD4+ lymphocytes and tumor type (p = 0.28). The study shows that both dMMR and PD-L1 expression is uncommon in tumor cells of both ductal and acinar adenocarcinoma of the prostate, while PD-L1 expression in tumor-infiltrating immune cells is a more common finding.

Identifiants

pubmed: 31127651
doi: 10.1111/apm.12970
doi:

Substances chimiques

B7-H1 Antigen 0
Biomarkers, Tumor 0
CD274 protein, human 0

Types de publication

Journal Article

Langues

eng

Pagination

554-560

Informations de copyright

© 2019 APMIS. Published by John Wiley & Sons Ltd.

Auteurs

Claes Lindh (C)

Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.

Lorand Kis (L)

Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.

Brett Delahunt (B)

Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand.

Hemamali Samaratunga (H)

Aquesta Uropathology and University of Queensland, Brisbane, Queensland, Australia.

John Yaxley (J)

Wesley Urology Clinic, Brisbane, Queensland, Australia.

Nils Peter Wiklund (NP)

Department of Molecular Medicine and Surgery (MMK), Karolinska Institutet, Stockholm, Sweden.

Mark Clements (M)

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

Lars Egevad (L)

Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH